MigVax, a Kiryat Shemona, Israel-based newly formed COVID-19 vaccine company, raised €12m in funding.
The round was led by OurCrowd.
The company intends to use the funds to accelerate path to clinical trials and bring its human coronavirus vaccine to market.
An affiliate of The Migal Galilee Research Institute, MigVax will develop a novel COVID-19 vaccine. is pioneering the effort to develop Israel’s human vaccine against COVID-19. The Migal Galilee Research Institute has previously developed a vaccine against infectious bronchitis virus, a coronavirus strain which causes bronchial disease affecting poultry. The safety and effectiveness of the poultry vaccine has been proven in animal trials carried out at Israel’s Veterinary institute. MigVax is using the methods learned from the existing vaccine to develop a new oral subunit human vaccine against COVID-19.